Circio Holding ASA — Share Issue/Capital Change 2026

Feb 14, 2026

Circio announces allocation of stock options to key employees

Circio announces allocation of stock options to key employees

Oslo, Norway, 14 February 2026 -- Circio Holding ASA (OSE: CRNA), a

biotechnology company developing novel circular RNA expression technology for

gene and cell therapy, today announces that the Board of Directors has

resolved to grant stock options to all of its employees. The option program is

as an important long-term incentive to retain key personnel and critical

expertise in the company. The option grant follows the completion of a high

successful rights issue and parallel private placements, raising close to NOK

70 million in gross proceeds.

On 12 January 2026, the Extraordinary General Meeting granted the Board of

Circio Holding ASA an authorization to increase the Company's share capital by

up to NOK 8,617,544.50 by issuing stock options and restricted stock units

(RSUs) under the Company s long-term incentive program, representing up to a

maximum of 10% of the Company's outstanding share capital prior to the Rights

Issue.

On 13 February, the Board resolved to issue a total of 3,700,000 stock options

to members of the executive management and a total of 1,300,000 stock options

to employees. Following the option grant, the total outstanding option pool is

approx. 8,700,000 options, representing a maximum of 4% dilution to the

current share float, if exercised in full.

Each option, when exercised, will give the right to acquire one share in the

Company. The options are granted without consideration. Pursuant to the

vesting schedule, 25% of the options will vest 12 months after the day of

grant (as long as the option holder is still employed). Thereafter, 1/36 of

the remaining options will vest each month as long as the option holder is

still employed, with the first 1/36 vesting 13 months after the day of grant.

Options that have not been exercised will lapse 7 years after the date of

grant.

The exercise price of the granted options is NOK 1.18. The exercise price is

equal to the volume weighted average trading price of the shares of the

Company on the Oslo Stock Exchange on the date of the grant, 13 February 2026.

Primary insiders in Circio Holding ASA have received the following options

grants, according to the terms described above:

* Chief Executive Officer Erik Digman Wiklund has been granted 1,200,000 share

options. Following the grant, he holds 728,133 shares and 2,000,011 options

in the Company.

* Chief Financial Officer Lubor Gaal has been granted 750,000 share options.

Following the grant, he holds 486,900 shares and 1,373,329 options in the

Company.

* Chief Technology Officer Thomas Birkballe Hansen has been granted 750,000

share options. Following the grant, he holds 315,600 shares and 1,166,658

options in the Company.

* Chief Scientific Officer Victor Levitsky has been granted 500,000 share

options. Following the grant, he holds 371,433 shares and 821,502 options in

the Company.

* Chief Operating Officer Ola Melin has been granted 500,000 share options.

Following the grant, he holds 261,766 shares and 824,185 options in the

Company.

Please see the attached forms for further details about the stock option

allocation.

This information is subject to the disclosure requirements pursuant to article

19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian

Securities Trading Act.

For further information, please contact:

Erik Digman Wiklund, CEO

Phone: +47 413 33 536

Email: erik.wiklund@circio.com

Lubor Gaal, CFO

Phone: +34 683 34 3811

Email: lubor.gaal@circio.com

About Circio

Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing novel circular RNA

expression technology for gene and cell therapy.

Circio has established a unique circular RNA (circRNA) vector expression

technology for next generation RNA, DNA and viral therapeutics. The

proprietary circVec platform is based on a modular genetic construct designed

for efficient biogenesis of multifunctional circRNA inside target cells. The

circVec platform has applications in multiple therapeutic settings, including

genetic medicine, cell therapy and chronic disease. It has demonstrated

75-fold increased RNA half-life and up to 40-fold enhanced protein expression

vs. conventional mRNA-based viral and non-viral vector systems, with the

potential to become a new gold-standard gene expression technology. The

circVec R&D activities are being conducted by the wholly owned subsidiary

Circio AB in Stockholm, Sweden.

In parallel, Circio is continuing to develop its legacy immuno-oncology

program, TG01, through cost-efficient external academic and industry

collaborations. TG01 targets RAS-mutated cancers and is being tested in two

clinical trials in Norway and the USA. TG01 is a therapeutic peptide vaccine

adjuvanted by STIMULON QS-21 licensed from Agenus Inc.